About OncoVEX GM-CSFOncoVEX GM-CSF is a first in class oncolytic vaccine.

In September 2009, the Company. Approval for a second Phase 3 trial in head and neck cancer, also under the SPA process.. About OncoVEX GM-CSFOncoVEX GM-CSF is a first in class oncolytic vaccine. OncoVEX replicates selectively in tumors, destroying cancer cells whist leaving surrounding healthy cells unharmed. OncoVEXGM-CSF to induce a strong immune response to kill cancer cells throughout the body. Process remote modes of action were at the clinic, where multiple with metastatic disease with metastatic disease at enrollment were validated advanced disease free.

Each issue features original scientific articles and clinical reports. Peer-reviewed articles cover topics in the field of oncology, gastrointestinal, vascular and transplant surgery. The journal also publishes papers of the meetings of its sponsoring societies, the Society of University Surgeons, the Central Surgical Association and the American Association of Endocrine Surgeons. Visit the journal website at.. ###About sURGERY, for 68 years, surgery has practical, reliable information on procedures, clinical advances approximately 7,000 employees the key trends shaping general surgery. Read the rest of this entry »

Gradual visioncataract.

Gradual visioncataract, the state of the changed refractive index in the lens of the eye, is the clouding of the eye is normally clear lens and results in blurred vision that often includes disturbing glare in the visual field. Successful treatment today involves the surgical removal of the affected lens and replacement with an artificial one.

The international team of scientists was able to position and is defective in the coding region of the gene by the analysis of genetic material from members of a large Swiss to identify families, most of them suffered from autosomal dominant juvenile cataract. The corresponding protein belongs to a family of monocarboxylate transporters, the small molecules move across cell membranes. Surprisingly, this genetic defect on even the state of renal glycosuria, a non – pathological kidney defect with elevated levels of glucose result not not in the blood.. Read the rest of this entry »

Casanova or caveman: Scientists isolate neurons.

Casanova or caveman: Scientists isolate neurons, choreographer male fly courtship A normal man, the first three steps in about two minutes is complete, Baker said. This is to lick about 2 minutes before he followed the first attempts copulation. Copulation itself lasts another 20 minutes. But if we interfere with the functioning of those 60 nerve cells, the male essentially skips the tapping step and attempts to do everything at once: He tries to copulate, lick their genitals and it is a love song to play at the same Sun which usually takes a total of reduced four minutes to – – and that’s very well very well. .

Reproductive failure – while some were pairing during the experiment, the mutant males failed to achieve their ultimate goal – reproductive success. – ‘The mutants have copulate, but it never resulted in fertilization, because it would consistently incorrectly transferred their sperm and other seminal contents,’Baker said. ‘There has to copulation copulation than normal males. That can be good, because for successful copulation, it female willingness that drives the whole thing. We can probably assume, if the mutant males behave in that way, they do things that can not find the female attractive. ‘. Read the rest of this entry »

About Eisai Medical Research Inc.

About Eisai Medical Research Inc.Eisai Medical Research Inc. Is a U.S. Pharmaceutical subsidiary of Eisai Co., Ltd. Eisai Co., Ltd. Is a research – based human health care company that discovers, develops and markets products in more than 30 countries. Eisai Medical Research Inc. Was founded in order exclusively clinical research clinical research and to accelerate clinical development of new chemical entities and new indications for marketed products.

Eisai initiated two Phase I studies of E7389 in 2003 and Phase II studies began in 2004.. E7389: A Cooperative Research and Development ProgramE7389 was developed through a joint program between the National Cancer Institute and Eisai Research Institute in Andover, Massachusetts. In 1992, ERI scientists determined that the anticancer activity of HB half of the molecule half of the molecule. Eisai Co. Finally isolated half after the synthesis of more than 200 analogues of this cancer. ERI and the NCI entered into a Cooperative Research and Development Agreement in 2001 and the first phase I study of E7389 was initiated in 2002. Read the rest of this entry »

A team of researchers at Concord Hospital in Sydney.

A team of researchers at Concord Hospital in Sydney, Australia, based mortality investigate the association between mortality and walking speed. Between January 2005 to June 2007, it was recruited 1705 men aged 70 years and over who. Lived in the inner city and in the suburbs of Sydney and participated in the Concord Health and Ageing in Men Project .

The researchers found a total of 266 deaths during follow-up. The results show that the average walking speed of the deceased 0.88 meters per second , and that none of the men with walking speeds of 1.36 m were / s or 3 miles per hour or greater were in contact with the Grim Reaper. According to the authors, the results of their study support their theory ‘that faster speeds are protective against mortality because fast walkers can maintain a safe distance from the Grim Reaper. Read the rest of this entry »

Page 3 of 3123